| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Proto-Oncogene Proteins c-bcl-2 | 8 | 2024 | 196 | 3.280 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 8 | 2023 | 884 | 2.150 |
Why?
|
| Bridged Bicyclo Compounds, Heterocyclic | 2 | 2024 | 88 | 1.700 |
Why?
|
| Cell Death | 3 | 2021 | 262 | 1.560 |
Why?
|
| Peptides | 7 | 2023 | 646 | 1.510 |
Why?
|
| Sulfonamides | 2 | 2024 | 318 | 1.490 |
Why?
|
| T-Lymphocytes, Regulatory | 2 | 2024 | 301 | 1.480 |
Why?
|
| Neuroblastoma | 4 | 2022 | 394 | 1.060 |
Why?
|
| Apoptosis | 10 | 2023 | 1713 | 0.990 |
Why?
|
| Th17 Cells | 1 | 2024 | 84 | 0.920 |
Why?
|
| Fetal Hemoglobin | 1 | 2023 | 14 | 0.920 |
Why?
|
| Stem Cell Transplantation | 3 | 2022 | 188 | 0.910 |
Why?
|
| Bcl-2-Like Protein 11 | 4 | 2020 | 23 | 0.890 |
Why?
|
| CRISPR-Cas Systems | 1 | 2023 | 71 | 0.870 |
Why?
|
| Transplants | 1 | 2023 | 42 | 0.870 |
Why?
|
| Erythrocytes | 1 | 2023 | 254 | 0.850 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2023 | 154 | 0.810 |
Why?
|
| Nucleic Acids | 1 | 2022 | 32 | 0.810 |
Why?
|
| Forkhead Transcription Factors | 1 | 2022 | 171 | 0.790 |
Why?
|
| Anemia, Sickle Cell | 1 | 2023 | 143 | 0.770 |
Why?
|
| Myeloproliferative Disorders | 1 | 2023 | 131 | 0.770 |
Why?
|
| T-Lymphocytes | 4 | 2023 | 1215 | 0.750 |
Why?
|
| Apoptosis Regulatory Proteins | 4 | 2014 | 201 | 0.710 |
Why?
|
| Immunotherapy | 2 | 2017 | 656 | 0.710 |
Why?
|
| Tumor Suppressor Protein p53 | 2 | 2023 | 408 | 0.680 |
Why?
|
| Mitochondrial Membranes | 1 | 2019 | 14 | 0.670 |
Why?
|
| Mitochondria | 3 | 2020 | 548 | 0.660 |
Why?
|
| Cathepsin B | 1 | 2017 | 12 | 0.610 |
Why?
|
| Reticulocytosis | 1 | 2017 | 1 | 0.600 |
Why?
|
| Anemia, Neonatal | 1 | 2017 | 5 | 0.600 |
Why?
|
| Antineoplastic Agents | 4 | 2024 | 2402 | 0.590 |
Why?
|
| Proto-Oncogene Proteins | 4 | 2014 | 661 | 0.590 |
Why?
|
| Bilirubin | 1 | 2017 | 130 | 0.580 |
Why?
|
| Cell Line, Tumor | 6 | 2024 | 2530 | 0.560 |
Why?
|
| Erythrocyte Transfusion | 1 | 2017 | 72 | 0.560 |
Why?
|
| Recovery of Function | 1 | 2017 | 289 | 0.540 |
Why?
|
| Thiamine | 1 | 2015 | 8 | 0.520 |
Why?
|
| Wernicke Encephalopathy | 1 | 2015 | 6 | 0.520 |
Why?
|
| Leukemia, Myeloid, Acute | 3 | 2021 | 782 | 0.520 |
Why?
|
| Hematologic Neoplasms | 2 | 2023 | 335 | 0.500 |
Why?
|
| Mice | 12 | 2024 | 11685 | 0.490 |
Why?
|
| beta-Thalassemia | 1 | 2013 | 6 | 0.470 |
Why?
|
| Myeloablative Agonists | 1 | 2013 | 36 | 0.460 |
Why?
|
| Cyclophosphamide | 1 | 2013 | 300 | 0.430 |
Why?
|
| Antibodies, Monoclonal | 3 | 2017 | 1401 | 0.430 |
Why?
|
| Membrane Proteins | 3 | 2014 | 1213 | 0.400 |
Why?
|
| Animals | 16 | 2024 | 27134 | 0.380 |
Why?
|
| Heart Diseases | 1 | 2013 | 297 | 0.380 |
Why?
|
| Neoplasms | 2 | 2023 | 2995 | 0.380 |
Why?
|
| Humans | 30 | 2024 | 88365 | 0.350 |
Why?
|
| Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 2 | 2023 | 54 | 0.320 |
Why?
|
| Drug Delivery Systems | 2 | 2022 | 179 | 0.320 |
Why?
|
| Child, Preschool | 5 | 2017 | 3673 | 0.320 |
Why?
|
| Protein Interaction Mapping | 2 | 2017 | 82 | 0.290 |
Why?
|
| Autografts | 2 | 2017 | 28 | 0.280 |
Why?
|
| Child | 5 | 2023 | 7082 | 0.260 |
Why?
|
| Killer Cells, Natural | 2 | 2002 | 273 | 0.230 |
Why?
|
| Hemoglobin, Sickle | 1 | 2023 | 19 | 0.230 |
Why?
|
| Antigens, CD34 | 1 | 2023 | 158 | 0.220 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2024 | 166 | 0.220 |
Why?
|
| Immunotherapy, Adoptive | 2 | 2022 | 186 | 0.220 |
Why?
|
| Protein Conformation, alpha-Helical | 1 | 2022 | 16 | 0.220 |
Why?
|
| CD3 Complex | 1 | 2002 | 134 | 0.210 |
Why?
|
| Pharmaceutical Preparations | 1 | 2023 | 91 | 0.210 |
Why?
|
| Mice, Inbred C57BL | 4 | 2024 | 3194 | 0.200 |
Why?
|
| B7-1 Antigen | 1 | 2002 | 76 | 0.200 |
Why?
|
| Antigens, Differentiation | 1 | 2002 | 141 | 0.200 |
Why?
|
| Immunity, Cellular | 1 | 2002 | 178 | 0.190 |
Why?
|
| Immunoconjugates | 1 | 2002 | 108 | 0.190 |
Why?
|
| Retinal Detachment | 1 | 2022 | 66 | 0.190 |
Why?
|
| T-Lymphocyte Subsets | 2 | 2020 | 274 | 0.190 |
Why?
|
| Lymphocyte Count | 2 | 2020 | 97 | 0.190 |
Why?
|
| Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2021 | 46 | 0.190 |
Why?
|
| Graft vs Host Disease | 2 | 2020 | 358 | 0.190 |
Why?
|
| Leukemia, Myeloid | 1 | 2002 | 249 | 0.190 |
Why?
|
| Tumor Microenvironment | 1 | 2024 | 448 | 0.190 |
Why?
|
| Lymphocytosis | 1 | 2020 | 11 | 0.180 |
Why?
|
| Flow Cytometry | 3 | 2019 | 691 | 0.180 |
Why?
|
| Thymocytes | 1 | 2020 | 31 | 0.180 |
Why?
|
| Antigens, CD | 1 | 2002 | 464 | 0.180 |
Why?
|
| Promoter Regions, Genetic | 1 | 2023 | 956 | 0.180 |
Why?
|
| Infant | 3 | 2017 | 3115 | 0.170 |
Why?
|
| Palliative Care | 1 | 2022 | 264 | 0.170 |
Why?
|
| Membrane Glycoproteins | 1 | 2002 | 431 | 0.170 |
Why?
|
| Mice, Knockout | 3 | 2020 | 1986 | 0.170 |
Why?
|
| Permeability | 1 | 2019 | 137 | 0.160 |
Why?
|
| Homeostasis | 1 | 2020 | 407 | 0.150 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2022 | 393 | 0.150 |
Why?
|
| Reticulocyte Count | 1 | 2017 | 2 | 0.150 |
Why?
|
| Protein Interaction Maps | 1 | 2017 | 49 | 0.150 |
Why?
|
| Surface-Active Agents | 1 | 2017 | 60 | 0.150 |
Why?
|
| Up-Regulation | 1 | 2020 | 729 | 0.150 |
Why?
|
| Fluorescence Resonance Energy Transfer | 1 | 2017 | 95 | 0.150 |
Why?
|
| Endosomes | 1 | 2017 | 78 | 0.150 |
Why?
|
| Proteolysis | 1 | 2017 | 106 | 0.140 |
Why?
|
| DNA-Directed RNA Polymerases | 1 | 2017 | 103 | 0.140 |
Why?
|
| Endocytosis | 1 | 2017 | 177 | 0.140 |
Why?
|
| Proteins | 1 | 2022 | 786 | 0.140 |
Why?
|
| Lipid Metabolism | 1 | 2017 | 199 | 0.140 |
Why?
|
| HeLa Cells | 1 | 2017 | 505 | 0.140 |
Why?
|
| Nanoparticles | 1 | 2017 | 162 | 0.140 |
Why?
|
| Protein Transport | 1 | 2017 | 419 | 0.130 |
Why?
|
| Lipids | 1 | 2017 | 269 | 0.130 |
Why?
|
| Disease-Free Survival | 2 | 2022 | 1212 | 0.130 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2023 | 2532 | 0.130 |
Why?
|
| Gene Expression Regulation | 1 | 2022 | 1972 | 0.120 |
Why?
|
| Cyclin D1 | 1 | 2013 | 84 | 0.120 |
Why?
|
| Lymphoma, Mantle-Cell | 1 | 2013 | 37 | 0.110 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2014 | 126 | 0.110 |
Why?
|
| Graft vs Leukemia Effect | 1 | 2013 | 11 | 0.110 |
Why?
|
| Fatal Outcome | 1 | 2013 | 295 | 0.110 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2014 | 340 | 0.100 |
Why?
|
| Immunophenotyping | 4 | 2013 | 216 | 0.100 |
Why?
|
| Allografts | 1 | 2013 | 176 | 0.100 |
Why?
|
| Skin | 1 | 2015 | 575 | 0.100 |
Why?
|
| Peptide Fragments | 1 | 2014 | 460 | 0.100 |
Why?
|
| Neoplasm Transplantation | 1 | 2012 | 396 | 0.100 |
Why?
|
| Male | 6 | 2017 | 41896 | 0.100 |
Why?
|
| Protein Structure, Secondary | 1 | 2012 | 331 | 0.100 |
Why?
|
| Retrospective Studies | 3 | 2022 | 8852 | 0.100 |
Why?
|
| Infant, Newborn | 1 | 2017 | 2441 | 0.100 |
Why?
|
| Transplantation, Heterologous | 1 | 2012 | 371 | 0.090 |
Why?
|
| Extracorporeal Membrane Oxygenation | 1 | 2013 | 177 | 0.090 |
Why?
|
| Myocardium | 1 | 2013 | 570 | 0.090 |
Why?
|
| Tumor Cells, Cultured | 2 | 2002 | 1057 | 0.090 |
Why?
|
| Recurrence | 1 | 2013 | 1170 | 0.090 |
Why?
|
| B-Lymphocytes | 1 | 2013 | 736 | 0.080 |
Why?
|
| Pulmonary Blastoma | 1 | 2008 | 5 | 0.080 |
Why?
|
| Disease Progression | 1 | 2013 | 1488 | 0.080 |
Why?
|
| BH3 Interacting Domain Death Agonist Protein | 1 | 2008 | 13 | 0.080 |
Why?
|
| Age Factors | 1 | 2013 | 1857 | 0.080 |
Why?
|
| Bone Marrow Neoplasms | 1 | 2007 | 18 | 0.070 |
Why?
|
| Treatment Outcome | 3 | 2022 | 8136 | 0.070 |
Why?
|
| Abdominal Neoplasms | 1 | 2007 | 39 | 0.070 |
Why?
|
| Pancreatitis | 1 | 2007 | 87 | 0.070 |
Why?
|
| Pleural Neoplasms | 1 | 2008 | 196 | 0.070 |
Why?
|
| CD8 Antigens | 2 | 2002 | 82 | 0.060 |
Why?
|
| CD4 Antigens | 2 | 2002 | 83 | 0.060 |
Why?
|
| Female | 4 | 2017 | 45621 | 0.060 |
Why?
|
| Adolescent | 1 | 2017 | 9138 | 0.060 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 2 | 2002 | 100 | 0.060 |
Why?
|
| Leukemia, T-Cell | 1 | 2004 | 17 | 0.060 |
Why?
|
| Leukemia, Lymphoid | 1 | 2004 | 72 | 0.060 |
Why?
|
| Antibodies, Neoplasm | 1 | 2004 | 84 | 0.060 |
Why?
|
| Time Factors | 1 | 2013 | 5302 | 0.060 |
Why?
|
| bcl-X Protein | 1 | 2023 | 54 | 0.060 |
Why?
|
| Myeloid Cell Leukemia Sequence 1 Protein | 1 | 2023 | 37 | 0.060 |
Why?
|
| HEK293 Cells | 2 | 2017 | 635 | 0.060 |
Why?
|
| Melphalan | 1 | 2023 | 98 | 0.050 |
Why?
|
| Prospective Studies | 2 | 2022 | 4263 | 0.050 |
Why?
|
| Adult | 2 | 2022 | 26266 | 0.050 |
Why?
|
| B7-2 Antigen | 1 | 2002 | 40 | 0.050 |
Why?
|
| Risk Factors | 1 | 2013 | 5435 | 0.050 |
Why?
|
| Abatacept | 1 | 2002 | 85 | 0.050 |
Why?
|
| Cell- and Tissue-Based Therapy | 1 | 2022 | 50 | 0.050 |
Why?
|
| CTLA-4 Antigen | 1 | 2002 | 137 | 0.050 |
Why?
|
| Cytotoxicity, Immunologic | 1 | 2002 | 213 | 0.050 |
Why?
|
| Signal Transduction | 3 | 2023 | 3360 | 0.050 |
Why?
|
| Induction Chemotherapy | 1 | 2022 | 149 | 0.050 |
Why?
|
| Neoplasm, Residual | 1 | 2022 | 176 | 0.050 |
Why?
|
| bcl-2-Associated X Protein | 2 | 2013 | 48 | 0.050 |
Why?
|
| Models, Molecular | 2 | 2017 | 1294 | 0.050 |
Why?
|
| Transplantation, Autologous | 1 | 2022 | 340 | 0.050 |
Why?
|
| Cell Division | 1 | 2002 | 696 | 0.050 |
Why?
|
| Transfection | 1 | 2002 | 913 | 0.040 |
Why?
|
| Leukocyte Transfusion | 1 | 1999 | 15 | 0.040 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2002 | 384 | 0.040 |
Why?
|
| Chimerism | 1 | 2020 | 37 | 0.040 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2023 | 611 | 0.040 |
Why?
|
| Protein Structure, Tertiary | 2 | 2013 | 740 | 0.040 |
Why?
|
| Inpatients | 1 | 2022 | 308 | 0.040 |
Why?
|
| Cytokines | 1 | 2002 | 801 | 0.040 |
Why?
|
| Protein Binding | 1 | 2002 | 1482 | 0.040 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2002 | 583 | 0.040 |
Why?
|
| Solutions | 1 | 2017 | 85 | 0.040 |
Why?
|
| Transplantation Conditioning | 1 | 2020 | 373 | 0.040 |
Why?
|
| Transplantation, Homologous | 1 | 2020 | 1001 | 0.040 |
Why?
|
| Healthcare Disparities | 1 | 2022 | 390 | 0.040 |
Why?
|
| Drug Carriers | 1 | 2017 | 82 | 0.040 |
Why?
|
| Biosensing Techniques | 1 | 2017 | 73 | 0.040 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2023 | 1349 | 0.030 |
Why?
|
| Regenerative Medicine | 1 | 2016 | 25 | 0.030 |
Why?
|
| RNA, Messenger | 1 | 2002 | 2002 | 0.030 |
Why?
|
| Drug Design | 1 | 2016 | 124 | 0.030 |
Why?
|
| Nanostructures | 1 | 2016 | 78 | 0.030 |
Why?
|
| Lung Neoplasms | 1 | 2008 | 2332 | 0.030 |
Why?
|
| Biocompatible Materials | 1 | 2016 | 198 | 0.030 |
Why?
|
| Prognosis | 1 | 2022 | 3746 | 0.030 |
Why?
|
| Caspase 7 | 1 | 2013 | 15 | 0.030 |
Why?
|
| Immunoenzyme Techniques | 1 | 2013 | 306 | 0.030 |
Why?
|
| Porosity | 1 | 2013 | 60 | 0.030 |
Why?
|
| Quinolines | 1 | 2014 | 91 | 0.030 |
Why?
|
| Imidazoles | 1 | 2014 | 151 | 0.030 |
Why?
|
| Caspase 3 | 1 | 2013 | 161 | 0.030 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2014 | 267 | 0.030 |
Why?
|
| Substrate Specificity | 1 | 2013 | 351 | 0.030 |
Why?
|
| Enzyme Activation | 1 | 2013 | 698 | 0.030 |
Why?
|
| Cell Cycle | 1 | 2013 | 508 | 0.030 |
Why?
|
| Proteomics | 1 | 2013 | 227 | 0.020 |
Why?
|
| Zebrafish | 1 | 2014 | 310 | 0.020 |
Why?
|
| Mice, Transgenic | 1 | 2013 | 1568 | 0.020 |
Why?
|
| Amino Acid Sequence | 1 | 2013 | 2063 | 0.020 |
Why?
|
| United States | 1 | 2022 | 6867 | 0.020 |
Why?
|
| MicroRNAs | 1 | 2014 | 551 | 0.020 |
Why?
|
| Molecular Sequence Data | 1 | 2013 | 3030 | 0.020 |
Why?
|
| Fluorescence Polarization | 1 | 2008 | 9 | 0.020 |
Why?
|
| Fluorescein-5-isothiocyanate | 1 | 2008 | 24 | 0.020 |
Why?
|
| Annexin A5 | 1 | 2008 | 20 | 0.020 |
Why?
|
| Cytochromes c | 1 | 2008 | 27 | 0.020 |
Why?
|
| Dextrans | 1 | 2008 | 77 | 0.020 |
Why?
|
| Liposomes | 1 | 2008 | 92 | 0.020 |
Why?
|
| Pneumonectomy | 1 | 2008 | 203 | 0.020 |
Why?
|
| Acute Disease | 1 | 2007 | 838 | 0.020 |
Why?
|
| Alemtuzumab | 1 | 2004 | 85 | 0.010 |
Why?
|
| Combined Modality Therapy | 1 | 2007 | 1710 | 0.010 |
Why?
|
| Mice, Inbred AKR | 1 | 1999 | 10 | 0.010 |
Why?
|
| Thy-1 Antigens | 1 | 1999 | 16 | 0.010 |
Why?
|
| Radiation Chimera | 1 | 1999 | 23 | 0.010 |
Why?
|
| Lymphocyte Depletion | 1 | 1999 | 97 | 0.010 |
Why?
|
| Histocompatibility Testing | 1 | 1999 | 138 | 0.010 |
Why?
|
| Major Histocompatibility Complex | 1 | 1999 | 82 | 0.010 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2008 | 2321 | 0.010 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 1 | 1999 | 135 | 0.010 |
Why?
|
| Isoantibodies | 1 | 1999 | 117 | 0.010 |
Why?
|
| Thymus Gland | 1 | 1999 | 197 | 0.010 |
Why?
|
| Spleen | 1 | 1999 | 431 | 0.010 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 1999 | 317 | 0.010 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2004 | 956 | 0.010 |
Why?
|
| Lymphocyte Activation | 1 | 1999 | 742 | 0.010 |
Why?
|
| Cell Differentiation | 1 | 1999 | 1511 | 0.010 |
Why?
|
| Middle Aged | 1 | 2004 | 25612 | 0.000 |
Why?
|